# Vertex Beta

VRTX | Stock | ## USD 312.22 9.10 2.83% |

Vertex Pharmaceuticals fundamentals help investors to digest information that contributes to Vertex Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Vertex Stock. The fundamental analysis module provides a way to measure Vertex Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vertex Pharmaceuticals stock.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Vertex | Beta |

## Vertex Beta Analysis

Vertex Pharmaceuticals' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it will be expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time. 2019 | 2020 | 2021 | 2022 (projected) | |

Receivables | 633.52 M | 885.35 M | 1.14 B | 1.23 B |

Inventories | 167.5 M | 280.78 M | 353.1 M | 380.98 M |

Beta | = | Covariance Variance |

## Current Vertex Pharmaceuticals Beta | 0.43 |

Most of Vertex Pharmaceuticals' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vertex Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

## Vertex Beta Driver Correlations

Understanding the fundamental principles of building solid financial models for Vertex Pharmaceuticals is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Beta. Since Vertex Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vertex Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vertex Pharmaceuticals' interrelated accounts and indicators.

**Click cells**to compare fundamentals

In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.

Compare to competition |

In accordance with the recently published financial statements, Vertex Pharmaceuticals has a Beta of 0.4321. This is 49.76% lower than that of the Biotechnology sector and 68.91% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.

## Vertex Beta Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vertex Pharmaceuticals' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vertex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Vertex Pharmaceuticals by comparing valuation metrics of similar companies.Vertex Pharmaceuticals is currently under evaluation in beta category among related companies.

## Vertex Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Vertex Pharmaceuticals from analyzing Vertex Pharmaceuticals' financial statements. These drivers represent accounts that assess Vertex Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Vertex Pharmaceuticals' important valuation drivers and their relationship over time.

2017 | 2018 | 2019 | 2020 | 2021 | 2022 (projected) | ||

Net Income Per Employee | 114.56 K | 838.76 K | 392.27 K | 795.36 K | 600.54 K | 647.95 K | |

Revenue Per Employee | 1.08 M | 1.22 M | 1.39 M | 1.82 M | 1.94 M | 2.1 M | |

Earnings Before Interest Taxes and Depreciation Amortization EBITDA | 103.26 M | 706.76 M | 1.5 B | 3.26 B | 2.91 B | 3.14 B |

## Vertex Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Vertex Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Vertex Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vertex Pharmaceuticals' value.Security Type | Shares | Value | ||

Zwj Investment Counsel Inc | Common Shares | 1.9 K | 445 K | |

Zwj Investment Counsel Inc | Common Shares | 1.9 K | 409 K | |

Zweigdimenna Associates Llc | Common Shares | 54.1 K | 11.6 M | |

Zweigdimenna Associates Llc | Common Shares | 151.2 K | 19 M | |

Zweigdimenna Associates Llc | Common Shares | 162.2 K | 19.3 M | |

Zweigdimenna Associates Llc | Common Shares | 98.8 K | 7.9 M | |

Zurich Insurance Group Ltd | Common Shares | 46.9 K | 7.9 M |

Let's try to break down what Vertex's beta means in this case. As returns on the market increase, Vertex Pharmaceuticals returns are expected to increase less than the market. However, during the bear market, the loss on holding Vertex Pharmaceuticals will be expected to be smaller as well.

## Vertex Fundamentals

Return On Equity | 0.29 % | |||

Return On Asset | 0.14 % | |||

Profit Margin | 0.38 % | |||

Operating Margin | 0.37 % | |||

Current Valuation | 73.55 B | |||

Shares Outstanding | 256.69 M | |||

Shares Owned by Insiders | 0.18 % | |||

Shares Owned by Institutions | 95.49 % | |||

Number of Shares Shorted | 3.03 M | |||

Price to Earning | 24.57 X | |||

Price to Book | 6.33 X | |||

Price to Sales | 9.37 X | |||

Revenue | 7.57 B | |||

Gross Profit | 3.62 B | |||

EBITDA | 2.92 B | |||

Net Income | 2.34 B | |||

Cash and Equivalents | 9.77 B | |||

Cash per Share | 38.06 X | |||

Total Debt | 824.6 M | |||

Debt to Equity | 0.06 % | |||

Current Ratio | 4.70 X | |||

Book Value Per Share | 50.77 X | |||

Cash Flow from Operations | 2.64 B | |||

Short Ratio | 1.88 X | |||

Earnings Per Share | 12.43 X | |||

Price to Earnings To Growth | 0.42 X | |||

Target Price | 323.94 | |||

Number of Employees | 3.9 K | |||

Beta | 0.43 | |||

Market Capitalization | 81.52 B | |||

Total Asset | 13.43 B | |||

Retained Earnings | (6.34 B) | |||

Working Capital | 900.8 M | |||

Current Asset | 1.41 B | |||

Current Liabilities | 506.35 M | |||

Z Score | 62.3 | |||

Net Asset | 13.43 B |

## About Vertex Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Vertex Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vertex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vertex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 00 people.
## Be your own money manager

Our tools can tell you how much better you can do entering a position in Vertex Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.## Did you try this?

### Run Competition Analyzer Now

## Competition AnalyzerAnalyze and compare many basic indicators for a group of related or unrelated entities |

All Next | Launch Module |

## Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Also, please take a look at Vertex Pharmaceuticals Piotroski F Score and Vertex Pharmaceuticals Altman Z Score analysis. You can also try Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

## Complementary Tools for analysis

When running Vertex Pharmaceuticals price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Transaction HistoryView history of all your transactions and understand their impact on performance | Go | |

Alpha FinderUse alpha and beta coefficients to find investment opportunities after accounting for the risk | Go | |

Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios | Go | |

Crypto CorrelationsUse cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | Go | |

Portfolio ManagerState of the art Portfolio Manager to monitor and improve performance of your invested capital | Go | |

Balance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratios | Go | |

Volatility AnalysisGet historical volatility and risk analysis based on latest market data | Go |

Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Vertex Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.